Selective inhibitors of cyclooxygenase (COX)-2 were developed to improve the safety of anti-inflammatory therapy in patients at elevated risk for gastrointestinal complications which are thought to be caused primarily by depression of COX-1 derived mucosal prostanoids...
Keywords: Clinical studies, atherothrombosis, atherosclerosis, inflammation, inflammatory mediators
10/2006 | Thrombosis and Haemostasis, Schattauer